Literature DB >> 8384733

Human cell mediated immunity to porins from Salmonella typhi.

F Blanco1, A Isibasi, C Raúl González, V Ortiz, J Paniagua, C Arreguín, J Kumate.   

Abstract

The current studies were undertaken to assess the role of the porins and outer membrane proteins (OMP) in the human immune response to Salmonella typhi 9, 12 Vi:d. Experiments were performed to determinate the lymphocyte activation response to porins in individuals who had been vaccinated against typhoid fever. 10 healthy volunteers were studied before and 10 days after oral or subcutaneous immunisation. Five patients with typhoid fever were also studied. Lymphocyte activation was measured by the 3H thymidine incorporation assay. Individuals with typhoid fever as well as those immunised with oral vaccine responded well to porins and outer membrane proteins, as opposed to those immunised with the subcutaneous vaccine. These results suggest that the porins and OMP play a role in the cellular immune response against Salmonella typhi.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384733

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  9 in total

1.  Salmonella Typhi OmpS1 and OmpS2 porins are potent protective immunogens with adjuvant properties.

Authors:  Mario A Moreno-Eutimio; Alejandra Tenorio-Calvo; Rodolfo Pastelin-Palacios; Christian Perez-Shibayama; Cristina Gil-Cruz; Rubén López-Santiago; Isabel Baeza; Marcos Fernández-Mora; Laura Bonifaz; Armando Isibasi; Edmundo Calva; Constantino López-Macías
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

2.  Salmonella porins induce a sustained, lifelong specific bactericidal antibody memory response.

Authors:  Ismael Secundino; Constantino López-Macías; Luisa Cervantes-Barragán; Cristina Gil-Cruz; Nora Ríos-Sarabia; Rodolfo Pastelin-Palacios; Miguel Angel Villasis-Keever; Ingeborg Becker; José Luis Puente; Edmundo Calva; Armando Isibasi
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

3.  Interaction of Salmonella typhi strains with cultured human monocyte-derived macrophages.

Authors:  D R Sizemore; E A Elsinghorst; L C Eck; A A Branstrom; D L Hoover; R L Warren; F A Rubin
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

4.  Human cell-mediated immune responses to antigenic fractions of Salmonella typhi.

Authors:  C Pérez; G M Calderón; C Ximénez; E I Melendro
Journal:  Immunology       Date:  1996-10       Impact factor: 7.397

5.  Identification of murine B-cell and T-cell epitopes of Escherichia coli outer membrane protein F with synthetic polypeptides.

Authors:  K M Williams; E C Bigley; R B Raybourne
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

6.  Identification of an I-Ed-restricted T-cell epitope of Escherichia coli outer membrane protein F.

Authors:  Kristina M Williams; Elmer C Bigley
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

Review 7.  The Subtleties and Contrasts of the LeuO Regulator in Salmonella Typhi: Implications in the Immune Response.

Authors:  Carmen Guadarrama; Tomás Villaseñor; Edmundo Calva
Journal:  Front Immunol       Date:  2014-12-12       Impact factor: 7.561

8.  Evolution of Salmonella Typhi outer membrane protein-specific T and B cell responses in humans following oral Ty21a vaccination: A randomized clinical trial.

Authors:  Juan Manuel Carreño; Christian Perez-Shibayama; Cristina Gil-Cruz; Constantino Lopez-Macias; Pietro Vernazza; Burkhard Ludewig; Werner C Albrich
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

9.  Conservation of the OmpC Porin Among Typhoidal and Non-Typhoidal Salmonella Serovars.

Authors:  Nuriban Valero-Pacheco; Joshua Blight; Gustavo Aldapa-Vega; Phillip Kemlo; Marisol Pérez-Toledo; Isabel Wong-Baeza; Ayako Kurioka; Christian Perez-Shibayama; Cristina Gil-Cruz; Luvia E Sánchez-Torres; Rodolfo Pastelin-Palacios; Armando Isibasi; Arturo Reyes-Sandoval; Paul Klenerman; Constantino López-Macías
Journal:  Front Immunol       Date:  2020-01-09       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.